REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
Zacks·2h ago
More News
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·7h ago
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9h ago
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Zacks·4d ago
Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks·5d ago
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
Zacks·5d ago
Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
Zacks·8d ago
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.